Table 3.

Recovery of Blood Counts Following the Third Intensification Course by Treatment Group

GroupNAZQ3-150 (mg/m2)G-CSFMedian Time to Recovery (days) and 95% CIHospitalizedMedian (range) Duration of Hospitalization (days)
(μ/kg)ANC ≥500PLT ≥20,000Both Counts3-151
28 28 34.8 (30, 40) 35.5 (28, 45) 42.3 (30, 47) 25 (96%)3-152 40 (11-91) 
34 24 30.6 (30, 34) 27.7 (24, 32) 33.7 (31, 41) 31 (97%) 30 (2-80) 
27 24 19.5 (18, 23) 18.8 (17, 26) 24.3 (22, 31) 20 (83%) 24 (6-44) 
34 28 21.9 (18, 28) 31.9 (21, 41) 35.6 (28, 43) 27 (87%) 20 (1-58) 
1 + 2 62 24/28 31.1 (31, 36) 30.2 (26, 38) 39.1 (32, 43) 56 (97%)  —  
3 + 4 61 24/28 20.5 (19, 24) 23.4 (19, 31) 29.1 (25, 36) 47 (85%)  —  
GroupNAZQ3-150 (mg/m2)G-CSFMedian Time to Recovery (days) and 95% CIHospitalizedMedian (range) Duration of Hospitalization (days)
(μ/kg)ANC ≥500PLT ≥20,000Both Counts3-151
28 28 34.8 (30, 40) 35.5 (28, 45) 42.3 (30, 47) 25 (96%)3-152 40 (11-91) 
34 24 30.6 (30, 34) 27.7 (24, 32) 33.7 (31, 41) 31 (97%) 30 (2-80) 
27 24 19.5 (18, 23) 18.8 (17, 26) 24.3 (22, 31) 20 (83%) 24 (6-44) 
34 28 21.9 (18, 28) 31.9 (21, 41) 35.6 (28, 43) 27 (87%) 20 (1-58) 
1 + 2 62 24/28 31.1 (31, 36) 30.2 (26, 38) 39.1 (32, 43) 56 (97%)  —  
3 + 4 61 24/28 20.5 (19, 24) 23.4 (19, 31) 29.1 (25, 36) 47 (85%)  —  

Abbreviation: N, number.

F3-150

All patients received 12 mg/m2 of mitoxantrone for 3 doses.

F3-151

Time to recovery of both ANC and platelets.

F3-152

Percent is based on number of patients with complete data on hospitalization.

or Create an Account

Close Modal
Close Modal